Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms
about
Potential role of dipeptidyl peptidase IV in the pathophysiology of heart failureInterplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathyDipeptidyl peptidase-4 inhibitor gemigliptin protects against vascular calcification in an experimental chronic kidney disease and vascular smooth muscle cells.Left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor- a pilot study.Triggering the succinate receptor GPR91 enhances pressure overload-induced right ventricular hypertrophy.Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetesSelective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetesTargeting metabolic disturbance in the diabetic heart.Updating experimental models of diabetic cardiomyopathyEffects of linagliptin and liraglutide on glucose- and angiotensin II-induced collagen formation and cytoskeleton degradation in cardiac fibroblasts in vitro.Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-κB/IκBα system through the activation of AMP-activated protein kinase.Sitagliptin attenuates cardiomyopathy by modulating the JAK/STAT signaling pathway in experimental diabetic rats.The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms.Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies.Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animalsThe Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class?Mechanisms for the cardiovascular effects of glucagon-like peptide-1.Arrhythmogenic gene remodelling in elderly patients with type 2 diabetes with aortic stenosis and normal left ventricular ejection fraction.Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial.Atorvastatin alleviates experimental diabetic cardiomyopathy by suppressing apoptosis and oxidative stress.Sitagliptin ameliorates high glucose-induced cell proliferation and expression of the extracellular matrix in glomerular mesangial cellsEstrogen deprivation aggravates cardiac hypertrophy in nonobese Type 2 diabetic Goto-Kakizaki (GK) rats.Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes.Effects of glucagon-like peptide-1 on advanced glycation endproduct-induced aortic endothelial dysfunction in streptozotocin-induced diabetic rats: possible roles of Rho kinase- and AMP kinase-mediated nuclear factor κB signaling pathways.Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: role of GLP-1 isoforms in Glut4 receptor trafficking.Voltage dependence of the Ca2+ transient in endocardial and epicardial myocytes from the left ventricle of Goto-Kakizaki type 2 diabetic rats.Sitagliptin ameliorates diabetic nephropathy by blocking TGF-β1/Smad signaling pathway.Effect of metformin and sitagliptin on doxorubicin-induced cardiotoxicity in adult male albino rats.Effects of dipeptidyl peptidase-4 inhibitors on cardiac and endothelial function in type 2 diabetes mellitus: A pilot study.Alleviation of renal mitochondrial dysfunction and apoptosis underlies the protective effect of sitagliptin in gentamicin-induced nephrotoxicity.Calcium Signaling in the Ventricular Myocardium of the Goto-Kakizaki Type 2 Diabetic Rat.
P2860
Q26829634-54DA1CE3-F8CB-4243-B6CC-205E03922ED7Q27001165-25E1E7C4-E2E1-4A06-B163-3B092A004749Q33883879-67A3DB2F-9D57-46B1-A2C5-A94E6B396B03Q34283308-94B22EE2-63BE-4FBA-93F1-EEBE9968E4A1Q34371092-01289F89-038F-4774-8309-5CF69B94243BQ34464759-BD117ABF-54F4-424C-8230-E9F05CB57F89Q34994502-35FF4F44-2CD0-486A-A364-DD20788FB56BQ35084845-5600A035-DA83-41E7-A485-E468964B2CD7Q35564129-7C9E3EB6-0502-4EAE-9753-A1D769843B8FQ36096985-69FCE6BB-8B30-45BD-AC8F-BCF18A36F7EFQ36901072-351722E3-4B98-4C5D-9AB7-B89FF67268CBQ37066737-D252DE36-6449-4DC2-96DB-1A6A9863A6D1Q37562145-3F860379-B35F-46BE-8F76-E203C8AFCBEDQ37611715-0D4412FC-F809-4FF0-8F09-A7DBEED8DFEAQ37725539-18844043-35A4-4346-8305-4BF85D9F18B2Q38527885-935B6DBF-EB46-4FA8-9C8E-2AF0739C2EF1Q38589032-4C25F9C3-8273-4754-8235-D1B8A1AD21ACQ38626456-491E5775-EC9A-4425-B5CC-E135E485D220Q39444439-984FA713-3915-4A7D-9974-4C1EECD460ABQ40871248-368DC24E-6371-4CA3-B708-EB47784F3AF2Q42376345-9074BC81-E73F-4080-80EB-D23328E2858EQ42379105-86ED99FC-8CB1-42E0-8EEB-3E0396ABE804Q42876331-111E854A-3BC6-4F5E-ABA7-36B32DDEFFD1Q46611689-365AF02C-61C8-4502-9BD7-22B3E4DFF9B3Q48043450-8A14ABFA-D445-4162-99CC-76DD5598E21FQ48274275-6069D8AD-6EFC-4325-8474-1924F309CB2AQ52684055-AF2B5CE1-4D00-4BE0-BC29-C5D113BED643Q52887129-81369467-7632-4998-B309-96407B2BAB35Q53145102-1C7B2ABB-C7EE-41B5-80FD-4E5CA854282FQ53622968-1B152DC2-E36B-4736-AC45-A9B802C784D6Q55049902-8233AC36-AB66-41E1-9CF4-E846F59A8990
P2860
Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Sitagliptin reduces cardiac ap ...... ential roles of GLP-1 isoforms
@ast
Sitagliptin reduces cardiac ap ...... ential roles of GLP-1 isoforms
@en
Sitagliptin reduces cardiac ap ...... ential roles of GLP-1 isoforms
@nl
type
label
Sitagliptin reduces cardiac ap ...... ential roles of GLP-1 isoforms
@ast
Sitagliptin reduces cardiac ap ...... ential roles of GLP-1 isoforms
@en
Sitagliptin reduces cardiac ap ...... ential roles of GLP-1 isoforms
@nl
prefLabel
Sitagliptin reduces cardiac ap ...... ential roles of GLP-1 isoforms
@ast
Sitagliptin reduces cardiac ap ...... ential roles of GLP-1 isoforms
@en
Sitagliptin reduces cardiac ap ...... ential roles of GLP-1 isoforms
@nl
P2093
P2860
P3181
P1433
P1476
Sitagliptin reduces cardiac ap ...... ential roles of GLP-1 isoforms
@en
P2093
Alicia Caro-Vadillo
Belén Picatoste
Cristian Iborra
Elisa Ramírez
Jesús Egido
Sara Ares-Carrasco
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0078330
P407
P577
2013-01-01T00:00:00Z